507
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Study of interaction between croscarmellose and escitalopram during sample preparation

&
Pages 1195-1199 | Received 08 Aug 2011, Accepted 18 Nov 2011, Published online: 27 Dec 2011

References

  • Huang WX, Desai M, Tang Q, Yang R, Vivilecchia RV, Joshi Y. (2006). Elimination of metformin-croscarmellose sodium interaction by competition. Int J Pharm, 311:33–39.
  • Hollenbeck RG, Mitrevej KT, Fan AC. (1983). Estimation of the extent of drug-excipient interactions involving croscarmellose sodium. J Pharm Sci, 72:325–327.
  • Díaz Ramírez CC, Robles LV. (2010). Surrogate functionality of celluloses as tablet excipients. Drug Dev Ind Pharm, 36:1422–1435.
  • Cory W, Field K, Wu-Linhares D. (2004). Is it the method or the process-separating the causes of low recovery. Drug Dev Ind Pharm, 30:891–899.
  • Claudius JS, Neau SH. (1998). The solution stability of vancomycin in the presence and absence of sodium carboxymethyl starch. Int J Pharm 168:41–48.
  • Golubitskii GB, Budko EV, Basova EM, Ivanov VM. (2008). Reaction of ephedrine hydrochloride with sodium crosscarmellose and its account in the analysis of ephedrine-containing preparations. J Anal Chem 63:162–165.
  • Arakawa T, Kita Y, Koyama AH. (2008). Solubility enhancement of gluten and organic compounds by arginine. Int J Pharm, 355:220–223.
  • Pignatello R, Ferro M, Puglisi G. (2002). Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions. AAPS PharmSciTech, 3:E10.
  • Adeyeye MC, Mwangi E, Katondo B, Jain A, Ichikawa H, Fukumori Y. (2005). Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process: I. Eudragit-based formulation and possible drug-excipient interaction. J Microencapsul, 22:333–342.
  • Pesonen T, Kanerva H, Hirvonen J, Nuuja T, Pohjola J. (1995). The incompatibilities between chlorhexidine diacetate and some tablet excipients. Drug Dev Ind Pharm 21:747–752.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.